106 related articles for article (PubMed ID: 1574245)
21. Cellular immunity in bladder cancer patients.
Guinan P; McKiel C; Flanagan M; Bhatti R; Pessis D; Ablin RJ
J Urol; 1978 Jun; 119(6):747-9. PubMed ID: 660759
[TBL] [Abstract][Full Text] [Related]
22. Effect of transcatheter renal arterial embolization combined with cryoablation on regulatory CD4+CD25+ T lymphocytes in the peripheral blood of patients with advanced renal carcinoma.
Li Y; Guo Z; Liu CF; Xing WG; Si TG; Liu F; Guo XY; Xing JZ
Cryobiology; 2012 Aug; 65(1):56-9. PubMed ID: 22521783
[TBL] [Abstract][Full Text] [Related]
23. [Zeta chain level of T and NK cells in patients with renal-cell carcinoma and bladder cancer and its clinical significance].
Han Y; Li CL; Lu L; Zhou CX; Ma WB; Wang DM; Zhang SR
Zhonghua Zhong Liu Za Zhi; 2004 Mar; 26(3):158-60. PubMed ID: 15196436
[TBL] [Abstract][Full Text] [Related]
24. Activated CD4-positive T-lymphocytes and impaired cell-mediated immunity in patients with carcinoma of the urinary bladder with schistosomiasis.
Raziuddin S; Shetty S; Ibrahim A; Patil K
Cancer; 1990 Feb; 65(4):931-9. PubMed ID: 1688730
[TBL] [Abstract][Full Text] [Related]
25. Critical evaluation of lymphocyte functions in urological cancer patients.
Elhilali MM; Paika KD; Brosman S; Fahey JL
Cancer Res; 1976 Jan; 36(1):132-7. PubMed ID: 1082369
[TBL] [Abstract][Full Text] [Related]
26. Concanavalin A-activated suppressor cell activity in peripheral blood lymphocytes of urologic cancer patients.
Catalona WJ; Ratliff TL; McCool RE
J Natl Cancer Inst; 1980 Sep; 65(3):553-7. PubMed ID: 6157855
[TBL] [Abstract][Full Text] [Related]
27. [Two-color flow cytometry analysis of lymphocyte subsets in patients with acute myocardial infarction and post-myocardial infarction syndrome].
Tsuchihashi M; Sakaguchi Y; Nakamura M; Sutani T; Tsuruta S; Kato S; Uemura S; Nishida Y; Hashimoto T; Kagoshima T
J Cardiol; 1995 Aug; 26(2):69-79. PubMed ID: 7674146
[TBL] [Abstract][Full Text] [Related]
28. [The study of infiltrating lymphocytes in the tissues of bladder carcinoma].
Fujimoto Y; Hasegawa Y; Kato N; Sakai S; Kuriyama M; Kawada Y; Nishiura T; Takeuchi T; Isogai K
Hinyokika Kiyo; 1983 Sep; 29(9):1037-45. PubMed ID: 6610297
[TBL] [Abstract][Full Text] [Related]
29. Suppressor cells in immunodepressed bladder and prostate cancer patients.
Herr HW
J Urol; 1980 May; 123(5):635-9. PubMed ID: 6448304
[TBL] [Abstract][Full Text] [Related]
30. [Monitoring of anti-tumour cell-mediated response in patients with renal cell carcinoma, disturbance of T cell proliferation].
Lukesová S; Vroblová V; Hlávková D; Kopecký O; Vokurková D; Morávek P; Safránek H; Soucek P
Vnitr Lek; 2008 Feb; 54(2):139-45. PubMed ID: 23687704
[TBL] [Abstract][Full Text] [Related]
31. Studies of the nonspecific cellular immune response in patients with urinary bladder carcinoma. II. Immunodepressive effect of sera from bladder carcinoma.
Nishio S; Horii A; Morikawa Y; Kawakita J; Nishijima T; Kishimoto T; Maekawa M
Invest Urol; 1979 Mar; 16(5):342-5. PubMed ID: 429128
[TBL] [Abstract][Full Text] [Related]
32. CD103+ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder.
Wang B; Wu S; Zeng H; Liu Z; Dong W; He W; Chen X; Dong X; Zheng L; Lin T; Huang J
J Urol; 2015 Aug; 194(2):556-62. PubMed ID: 25752441
[TBL] [Abstract][Full Text] [Related]
33. [De novo urological neoplasms in kidney transplant patients: experience in 1,751 patients].
di Capua Sacoto C; Luján Marco S; Bahilo Mateu P; Budía Alba A; Pontones Moreno JL; Jiménez Cruz JF
Actas Urol Esp; 2010 Jan; 34(1):88-94. PubMed ID: 20223138
[TBL] [Abstract][Full Text] [Related]
34. [Analysis of serum T-lymphocyte subsets and NK cell activity in patients with hypopharyngeal squamous cell carcinoma].
Chen WK; Song M; Chen FJ; Guo ZM; He LR; Yan SL
Ai Zheng; 2006 Oct; 25(10):1300-2. PubMed ID: 17059781
[TBL] [Abstract][Full Text] [Related]
35. Dominance of CD4+ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma.
Ebelt K; Babaryka G; Figel AM; Pohla H; Buchner A; Stief CG; Eisenmenger W; Kirchner T; Schendel DJ; Noessner E
Prostate; 2008 Jan; 68(1):1-10. PubMed ID: 17948280
[TBL] [Abstract][Full Text] [Related]
36. [Analysis of serum T-lymphocyte subsets and NK cell activity in patients with squamous cell carcinoma of pharynx and larynx].
Chen W; Wang X; Tao R
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2011 Dec; 25(24):1105-7. PubMed ID: 22390028
[TBL] [Abstract][Full Text] [Related]
37. [Detection of circulating immune complexes by polyethyleneglycol precipitations complement consumption test in urological malignant diseases].
Sakai S; Kato N; Ito Y; Matsuda S; Koide T; Deguti T; Kuriyama M; Ban Y; Nishiura T; Tei K
Hinyokika Kiyo; 1984 Nov; 30(11):1611-7. PubMed ID: 6543290
[TBL] [Abstract][Full Text] [Related]
38. Predictive value of CD8highCD57+ lymphocyte subset in interferon therapy of patients with renal cell carcinoma.
Characiejus D; Pasukoniene V; Kazlauskaite N; Valuckas KP; Petraitis T; Mauricas M; Den Otter W
Anticancer Res; 2002; 22(6B):3679-83. PubMed ID: 12552976
[TBL] [Abstract][Full Text] [Related]
39. Soluble CD44 variants in the serum of patients with urological malignancies.
Lein M; Jung K; Weiss S; Schnorr D; Loening SA
Oncology; 1997; 54(3):226-30. PubMed ID: 9143404
[TBL] [Abstract][Full Text] [Related]
40. [Changes in the mechanical integration of transitional epithelial cells and in the immune status of patients with bladder tumors].
Bocharova OA; Serebriakova RV; Golubeva VA; Figurin KM; Bukharkin BV; Bodrova NB; Matveev BP; Baryshnikov AIu
Urol Nefrol (Mosk); 1994; (3):27-30. PubMed ID: 8079407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
